Login / Signup

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.

Karissa M JohnstonLauren PowellEvan PopoffLinda HarrisRobert CroopVladimir CoricGilbert L'Italien
Published in: The Clinical journal of pain (2022)
The benefit-risk profiles of lasmiditan, rimegepant, and ubrogepant may improve clinical decision-making.
Keyphrases
  • decision making
  • respiratory failure
  • drug induced
  • combination therapy
  • aortic dissection
  • acute respiratory distress syndrome
  • extracorporeal membrane oxygenation
  • replacement therapy
  • smoking cessation